Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

Kayvon Pedram(Howard Hughes Medical Institute), D. Judy Shon(Stanford University), Gabrielle S. Tender(Stanford University), Natália Rodrigues Mantuano(University of Basel), Jason J. Northey(University of California, San Francisco), Kevin J. Metcalf(University of California, San Francisco), Simon Wisnovsky(University of British Columbia), Nicholas M. Riley(Stanford University), Giovanni C. Forcina(Stanford University), Stacy A. Malaker(Yale University), Angel Kuo(Stanford University), Benson M. George(Brigham and Women's Hospital), Caitlyn L. Miller(Stanford University), Kerriann M. Casey(Stanford University), José G. Vilches-Moure(Stanford University), Michael J. Ferracane(University of Redlands), Valerie M. Weaver(University of California, San Francisco), Heinz Läubli(University of Basel), Carolyn R. Bertozzi(Howard Hughes Medical Institute)
Nature Biotechnology
August 3, 2023
Cited by 86Open Access
Full Text

Abstract

Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Here, to expand the landscape of targetable substrates, we designed degraders that achieve substrate selectivity via recognition of a discrete peptide and glycan motif and achieve cell-type selectivity via antigen-driven cell-surface binding. We applied this approach to mucins, O-glycosylated proteins that drive cancer progression through biophysical and immunological mechanisms. Engineering of a bacterial mucin-selective protease yielded a variant for fusion to a cancer antigen-binding nanobody. The resulting conjugate selectively degraded mucins on cancer cells, promoted cell death in culture models of mucin-driven growth and survival, and reduced tumor growth in mouse models of breast cancer progression. This work establishes a blueprint for the development of biologics that degrade specific protein glycoforms on target cells.


Related Papers